High-dose cyclophosphamide without stem-cell rescue for refractory CIDP

T. H. Brannagan; A. Pradhan; T. Heiman-Patterson; A. C. Winkelman; M. J. Styler; D. L. Topolsky; P. A. Crilley; R. J. Schwartzman; I. Brodsky; D. E. Gladstone

doi:10.1212/WNL.58.12.1856

High-dose cyclophosphamide without stem-cell rescue for refractory CIDP

T. H. Brannagan, A. Pradhan, T. Heiman-Patterson, A. C. Winkelman, M. J. Styler, D. L. Topolsky, P. A. Crilley, R. J. Schwartzman, I. Brodsky, D. E. Gladstone

Research output: Contribution to journal › Article › peer-review

98 Scopus citations

Abstract

Four patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who were refractory to conventional treatment were treated with high-dose cyclophosphamide (200 mg/kg over 4 days). All improved in functional status and muscle strength. Nerve conduction studies improved in three of four. Other immunomodulatory medications have been discontinued. High-dose cyclophosphamide can be given safely to patients with CIDP and patients with disease persistence after standard therapy may have a response that lasts for over 3 years and results in long-term disease remission.

Original language	English (US)
Pages (from-to)	1856-1858
Number of pages	3
Journal	Neurology
Volume	58
Issue number	12
DOIs	https://doi.org/10.1212/WNL.58.12.1856
State	Published - Jun 25 2002
Externally published	Yes

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1212/WNL.58.12.1856

Cite this

@article{e815827918ee40c18854d5f15d825f45,

title = "High-dose cyclophosphamide without stem-cell rescue for refractory CIDP",

abstract = "Four patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who were refractory to conventional treatment were treated with high-dose cyclophosphamide (200 mg/kg over 4 days). All improved in functional status and muscle strength. Nerve conduction studies improved in three of four. Other immunomodulatory medications have been discontinued. High-dose cyclophosphamide can be given safely to patients with CIDP and patients with disease persistence after standard therapy may have a response that lasts for over 3 years and results in long-term disease remission.",

author = "Brannagan, {T. H.} and A. Pradhan and T. Heiman-Patterson and Winkelman, {A. C.} and Styler, {M. J.} and Topolsky, {D. L.} and Crilley, {P. A.} and Schwartzman, {R. J.} and I. Brodsky and Gladstone, {D. E.}",

year = "2002",

month = jun,

day = "25",

doi = "10.1212/WNL.58.12.1856",

language = "English (US)",

volume = "58",

pages = "1856--1858",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "12",

}

TY - JOUR

T1 - High-dose cyclophosphamide without stem-cell rescue for refractory CIDP

AU - Brannagan, T. H.

AU - Pradhan, A.

AU - Heiman-Patterson, T.

AU - Winkelman, A. C.

AU - Styler, M. J.

AU - Topolsky, D. L.

AU - Crilley, P. A.

AU - Schwartzman, R. J.

AU - Brodsky, I.

AU - Gladstone, D. E.

PY - 2002/6/25

Y1 - 2002/6/25

N2 - Four patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who were refractory to conventional treatment were treated with high-dose cyclophosphamide (200 mg/kg over 4 days). All improved in functional status and muscle strength. Nerve conduction studies improved in three of four. Other immunomodulatory medications have been discontinued. High-dose cyclophosphamide can be given safely to patients with CIDP and patients with disease persistence after standard therapy may have a response that lasts for over 3 years and results in long-term disease remission.

AB - Four patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who were refractory to conventional treatment were treated with high-dose cyclophosphamide (200 mg/kg over 4 days). All improved in functional status and muscle strength. Nerve conduction studies improved in three of four. Other immunomodulatory medications have been discontinued. High-dose cyclophosphamide can be given safely to patients with CIDP and patients with disease persistence after standard therapy may have a response that lasts for over 3 years and results in long-term disease remission.

UR - http://www.scopus.com/inward/record.url?scp=0037172884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037172884&partnerID=8YFLogxK

U2 - 10.1212/WNL.58.12.1856

DO - 10.1212/WNL.58.12.1856

M3 - Article

C2 - 12084892

AN - SCOPUS:0037172884

SN - 0028-3878

VL - 58

SP - 1856

EP - 1858

JO - Neurology

JF - Neurology

IS - 12

ER -

High-dose cyclophosphamide without stem-cell rescue for refractory CIDP

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this